Lilly Defeats Cymbalta Label Suit As Possible MDL Looms

Law360, San Diego (November 7, 2014, 8:40 PM EST) -- A New York federal judge on Friday ruled Eli Lilly & Co.’s label for antidepressant drug Cymbalta adequately warned doctors about possible withdrawal symptoms and tossed a suit claiming the label was inaccurate, potentially hurting the plaintiffs’ chances to consolidate more than two dozen similar cases in multidistrict litigation.

U.S. District Judge Robert W. Sweet granted Eli Lilly's summary judgment bid, finding its label properly described the potential negative effects of stopping the drug and did not mislead medical professionals. The judge also ruled that plaintiff...
To view the full article, register now.




Case Information

Case Title

McDowell v. Eli Lilly and Company

Case Number



New York Southern

Nature of Suit

Personal Inj. Prod. Liability


Robert W. Sweet

Date Filed

June 4, 2013

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.